A Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults with Refractory Relapsing or Progressing Multiple Sclerosis

16786D831DC00001OpenA Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults with Refractory Relapsing or Progressing Multiple SclerosisIndustrialAdultTreatmentIOtherBarry, BrianMedstar Washington Hospital Center : Anu Bhooshan16668Anu BhooshanAnu Bhooshananu.r.bhooshan@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>